Psychiatrists and neuroscientists at Geneva University Hospitals (HUG) and the University of Geneva (UNIGE) are pioneering precision psychiatry by integrating artificial intelligence (AI) with personalized brain stimulation. This innovative approach aims to move beyond traditional trial-and-error treatment methods for mental health disorders, which can be lengthy and lead to patient suffering. By analyzing a patient's clinical history, biological data, and brain scans using AI, clinicians hope to predict the most effective therapy—whether medication, psychotherapy, or neuromodulation—for individual patients. A key focus is on transcranial magnetic stimulation (TMS), where individual brain circuits are mapped to optimize stimulation targets, particularly for negative symptoms of schizophrenia like apathy, with trials showing promising results and potential for regulatory approval by 2030.